Workflow
Intellectual property
icon
Search documents
Worksport .(WKSP) - 2025 Q2 - Earnings Call Transcript
2025-08-13 18:00
Worksport (WKSP) Q2 2025 Earnings Call August 13, 2025 01:00 PM ET Speaker0Good afternoon, everyone, and thank you for joining WorkSports quarter '2 twenty twenty May. I'm Steven Rossi, chief executive officer of WorkSports, and with me today is our chief financial officer, Michael Johnston. This quarter represents another significant step forward in our growth story. We achieved record quarterly revenues, meaningfully expanded our gross margins, and continue to build the operational commercial foundation t ...
X @Wu Blockchain
Wu Blockchain· 2025-07-31 13:13
Grayscale has announced the launch of Grayscale Story Trust, which provides investors with exposure to the native token IP of the Story network. Story is a blockchain network that powers programmable intellectual property. https://t.co/UOfPsFUDEx ...
How corporations use Ireland to dodge taxes
CNBC· 2025-07-10 16:01
A large range of American companies stow their intellectual property in Ireland. To illustrate this, let's pretend to set up our own multinational tech firm, Big Comp. Big Comp's assets are entirely controlled by a holding company that's based in the US. It's called Big Comp Holding Company, and it has a subsidiary, Big Comp International.The subsidiary is based in Ireland, where tax rates are relatively low. Big Comp is working on a new smart device. The Irish subsidiary buys licenses for its hardware, sof ...
How Companies From Apple To Pfizer Use Ireland To Dodge Taxes
CNBC· 2025-06-13 16:00
Over the past three decades. US corporations set up shop in Ireland. In 1996, about 3% of US businesses with global operations had Irish affiliates.By 2022, 25% of them opened Irish businesses. You really cannot talk about US multinationals in the last few decades without talking about Ireland. Big US corporations, that's technology companies like Apple, Microsoft or big pharmaceutical companies like Pfizer.Their tax strategies for, for many decades at least, were built around the role of Ireland. Something ...
RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107
Prnewswire· 2025-04-28 11:03
Core Insights - RedHill Biopharma has received a critical composition-of-matter patent for RHB-107, enhancing its market exclusivity in the COVID-19 therapeutic space, which is projected to exceed $3 billion by 2025 [1][2] - RHB-107 has shown promising results in a U.S. Phase 2 study, achieving a 100% reduction in hospitalization rates among treated patients compared to a 15% hospitalization rate in the placebo group [2] - The drug is designed to be a broad-acting antiviral that targets human serine proteases, potentially effective against various SARS-CoV-2 variants [3][4] Company Overview - RedHill Biopharma focuses on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology, with a notable product being Talicia for H. pylori infection [5] - The company has a diverse pipeline, including RHB-204 for Crohn's disease and opaganib for cancer and COVID-19, indicating a strong commitment to addressing multiple health challenges [5] Clinical Data - In the Phase 2 study, RHB-107 demonstrated a 100% reduction in hospitalization (0/41) versus 15% (3/20) in the placebo group, with a nominal p-value of 0.0317, and an 88% reduction in new severe COVID-19 symptoms [2] - The study also indicated faster recovery times, with a median recovery of 3 days for RHB-107 compared to 8 days for placebo [2] Patent and Market Position - The newly allowed patent in China strengthens RedHill's intellectual property portfolio and expands its presence in Asia, a significant pharmaceutical market [2] - RHB-107's unique mechanism of action, targeting host cells rather than the virus directly, positions it as a potential alternative to existing treatments like Pfizer's Paxlovid [2][3]